Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Cablivi (caplacizumab) for the Treatment of Acquired Thrombotic Thrombocytopenic Purpura

Cablivi™ is the first therapeutic approved for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP). Image courtesy of Ablynx.

  • Cablivi (caplacizumab)
  • Cablivi (caplacizumab)
  • Cablivi (caplacizumab)

Go Top